PatentsGlobal
Akebia Therapeutics has obtained a new U.S. patent for Vafseo® (vadadustat), an oral treatment for anemia due to chronic kidney disease (CKD) in dialysis patients. Issued by the USPTO on November 17, 2026, the patent extends protection until January 18, 2043, and covers methods to modulate drug-drug interactions durin…
Wednesday, November 18, 2026
TrademarksUSA
Akebia Therapeutics has been granted a U.S. patent extending intellectual property protection for its anemia treatment Vafseo® (vadadustat) until January 18, 2043. The patent, covering methods addressing drug-drug interactions, is eligible for Orange Book listing, reinforcing Vafseo’s market exclusivity. Approved by t…
Tuesday, November 17, 2026
PatentsGlobal
Akebia Therapeutics has been granted a new patent and qualified for a five-year patent term extension on its composition of matter patent for Vafseo® (vadadustat). This development strengthens the company’s intellectual property portfolio and extends market exclusivity for Vafseo®—an oral treatment for anemia due to c…
Wednesday, June 10, 2026